All In Biotech

Drug Trial Radar · NCT03336619

A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza

Last checked: Nov 20, 2026Latest source record: Jun 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,030 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,030

Actual

Start

Jan 17, 2018

Primary completion

Apr 17, 2019

Study completion Apr 17, 2019

Sponsor

Lead sponsor
Romark Laboratories L.C.Industry
Sponsor type
Industry
First posted
Nov 8, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Trial to evaluate efficacy and safety of nitazoxanide (NTZ) in the treatment of uncomplicated influenza.

Conditions

  • Influenza

Interventions

  • NitazoxanideDrug

    Nitazoxanide 600 mg administered orally twice daily for five days

  • PlaceboDrug

    Placebo administered orally twice daily for five days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time From First Dose to Symptom ResponseTime frame: Up to 21 days

Locations

38 sites in 3 countries. Site status is shown where the registry gives one.

  • Vanguard Study Site

    Alabaster, Alabama

  • Vanguard Study Site

    Birmingham, Alabama

  • Vanguard Study Site

    Birmingham, Alabama

  • Vanguard Study Site

    Hoover, Alabama

  • Vanguard Study Site

    Pelham, Alabama

  • Vanguard Study Site

    Goodyear, Arizona

  • Vanguard Study Site

    Tolleson, Arizona

  • Vanguard Study Site

    Hot Springs, Arkansas

  • Vanguard Study Site

    Anaheim, California

  • Vanguard Study Site

    Westminster, California

  • Vanguard Study Site

    Lauderdale Lakes, Florida

  • Vanguard Study Site

    Orlando, Florida

  • Vanguard Study Site

    Valparaiso, Indiana

  • Vanguard Study Site

    New Orleans, Louisiana

  • Vanguard Study Site

    St Louis, Missouri

  • Vanguard Study Site

    Missoula, Montana

  • Vanguard Study Site

    Brooklyn, New York

  • Vanguard Study Site

    Cincinnati, Ohio

  • Vanguard Study Site

    Columbus, Ohio

  • Vanguard Study Site

    Dayton, Ohio

  • Vanguard Study Site

    Medford, Oregon

  • Vanguard Study Site

    Rapid City, South Dakota

  • Vanguard Study Site

    Jackson, Tennessee

  • Vanguard Study Site

    Smyrna, Tennessee

  • Vanguard Study Site

    Austin, Texas

  • Vanguard Study Site

    Carrollton, Texas

  • Vanguard Study Site

    Dallas, Texas

  • Vanguard Study Site

    Dallas, Texas

  • Vanguard Study Site

    Fort Worth, Texas

  • Vanguard Study Site

    Houston, Texas

  • Vanguard Study Site

    Pharr, Texas

  • Vanguard Study Site

    Plano, Texas

  • Vanguard Study Site

    Plano, Texas

  • Vanguard Study Site

    St. George, Utah

  • Vanguard Study Site

    Morayfield, Queensland, Australia

  • Vanguard Study Site

    Sherwood, Queensland, Australia

  • Vanguard Study Site

    Victoria Point, Queensland, Australia

  • Vanguard Study Site

    Ponce, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.